CUSTOMER SUPPORT CUSTOMER SUPPORT 022-4603 7236

fund search

Individually analyse each scheme and narrow your options further Every minute detail you need to know about scheme of your choice from asset holdings, best and worst performance and fund returns to competitor analysis; is available in the Fund card.
Using this report card, you can gather vital information regarding the future health of the scheme by analysing the top 10 companies and sectors it invests in. You can also track the fund management’s track record and analyse the philosophy behind scheme’s holdings. All the parameters in the fund card are extremely important and can go a long way in helping you decide which scheme to invest your money.

NAV As on Apr-19-2024

Tata India Pharma & Healthcare Fund(G)-Direct Plan

Top 10 Holdings
Company
(%)
Sun Pharmaceutical Industries Ltd.
14.56
Lupin Ltd.
9.39
Aurobindo Pharma Ltd.
8.87
Cipla Ltd.
7.07
Zydus Lifesciences Ltd.
5.40
Dr. Reddy's Laboratories Ltd.
5.08
Apollo Hospitals Enterprise Ltd.
4.26
Divi's Laboratories Ltd.
4.12
Fortis Healthcare Ltd.
4.09
Alkem Laboratories Ltd.
3.83
Top 10 Sectors
Sectors
(%)
Pharmaceuticals & Drugs
78.22
Hospital & Healthcare Services
13.21
Business Support
3.27
Fertilizers
0.73
Chemicals
0.43
Asset Allocation
Market Cap Allocation
  Scheme Benchmark ()
Large-Cap 38.27 NA
Mid-Cap 38.58 NA
Small-Cap 16.60 NA

Best and Worst Performance and Ratios

Best Performance in a year
Period Fund (%) Benchmark (%)
Year 23/03/20
to 23/03/21
76.35NA
Worst Performance in a year
Period Fund (%) Benchmark (%)
Year 08/09/16
to 08/09/17
-17.32NA
Ratios
Standard Deviation[%] 13.73
Sharpe Ratio [%] 1.19
Turnover Ratio [%] 31.34
Modified Duration
YTM
Riskometer
very high risk

Investors understand that their principal will be at very high risk

Fund Details
Category
Sector Funds
Inception Date (Regular Plan)
28-Dec-15
Inception Date (Direct Plan)
28-Dec-15
Expense Ratio (Direct Plan) %
0.83
Expense Ratio (Regular Plan) %
2.24
Investing Style
Large Growth
Fund Manager
Meeta Shetty
Scheme Benchmark
NIFTY PHARMA - TRI
AUM (Rs. in Cr.)
878.70
Fund Objective

Investment objective of the scheme is to provide long term capital appreciation by investing predominantly in equity/equity related instruments of the companies in the Pharma&Healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.

Growth Chart of the Scheme Versus Benchmark (SIP value Rs10,000)
Tata India Pharma & Healthcare Fund(G)-Direct Plan NIFTY PHARMA - TRI

Performance Comparison with similar Schemes and Benchmark